Insider Trading Alert: Special Diversified Opportunities Inc. $SDOI

wall-street-621097_1920

Special Diversified Opportunities Inc. (SDOI) insider have most recently took part in a trading activity. On Dec 4, 2017 Standard General L.p., 10% Owner bought 14,088 shares having total worth of $138,062 at the price of $9.8 per share, following the transaction a total of 7,258,918 shares owned by Standard General L.p..

Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.

Shares of Special Diversified Opportunities Inc. (SDOI) traded up 4.07% on May 30, 2017, hitting $0.87. 1,795 shares of the company’s stock traded hands. Special Diversified Opportunities Inc. has a 52 week low of $0.74 and a 52 week high of $1.13. The company’s market cap is $0 million.

Strategic Diagnostics, Inc., is a Delaware corporation formed in 1990. It is a biotechnology company which develops, commercializes and markets products and solutions that preserve and enhance the quality of human health and wellness. It is a provider of a range of life sciences products and services, including custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services. The Company’s products and services are sold to, and often incorporated in the production process for other commercial products used by a range of customers including pharmaceutical, biotechnology and diagnostic companies, and major biomedical research centers both domestically and internationally. The Company produces antibodies to targets and biomarkers of interest allowing customers to quickly assess the feasibility, efficacy and safety of compounds in their developmental pipelines. The Company’s main business activities are in two areas, Life Sciences Research Antibodies and Assay Development and In vitro Diagnostic antibody reagents. The Company has substantial resources towards the development of its proprietary Genomic Antibody Technology (‘GAT’) program, with the intent of making this program a key element of the Company’s Life Sciences strategy for establishing and maintaining sustainable differentiation in key markets. GAT was developed to address this growing need for high quality reagents. The Company’s main competitors include Covance (public), Harlan (private), Lampire (private), HyTest (private) and Scantibodies (private).

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.